Bristol Myers Squibb clocked $10 million in sales for new schizophrenia drug Cobenfy in the fourth quarter of 2024, with the ...

DelveInsight’s, “Schizophrenia Pipeline Insight” report provides comprehensive insights about 55+ companies and 60+ pipeline drugs in Schizophrenia pipeline landscape. It covers the Schizophrenia ...

Below is a review of novel drug and biological products approved by the Food and Drug Administration (FDA) in 2024. The list includes several groundbreaking therapies that are expected to change the ...

(“Neurocrine”) regarding the clinical development of its partnered muscarinic agonist portfolio. These updates were presented by Neurocrine at the 43 rd Annual J.P. Morgan Healthcare Conferen ...

Ltd. (“Nxera” or “the Company”; TSE 4565) is pleased to report on progress being made by Neurocrine Biosciences, Inc. (“Neurocrine”) regarding the clinical development of its partnered muscarinic ...

Ltd. ("Nxera” or "the Company”; TSE 4565) is pleased to report on progress being made by Neurocrine Biosciences, Inc. ("Neurocrine”) regarding the clinical development of its partnered muscarinic ...

Hope is not passive wishing but an active, dynamic process. According to Hope Theory, hope involves two components: agency and pathways. Agency is the belief in one’s capability to act ...

Treatment response lasted for at least 12 months in 39% of study participants who were responsive to the therapy. While Cobenfy proved the potential of targeting the muscarinic pathway in ...

It works by blocking M1 muscarinic receptors, which are found particularly in OPCs close to MS lesions with ongoing inflammation. The trial is designed to show evidence of remyelination as a ...

This discrepancy indicates that the etching procedure introduced extraneous conductive pathways unrelated to the VHE, thereby explaining why a reduced band gap had been observed in prior ...

Credit: Getty Images. The FDA approved a wide range of therapies in 2024, including many new molecular entities and biological products. Below is a review of novel drug and biological products ...